Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil C Dalvie

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Microbial Cell Factories|July 31, 2024
CRISPR-Cas9 knockout screen informs efficient reduction of the Komagataella phaffii secretomeNeil C Dalvie, Timothy R Lorgeree, Yuchen Yang, et al.
Cold Spring Harbor Perspectives in Biology|October 3, 2023
Microbial Catalysis for CO<sub>2</sub> Sequestration: A Geobiological ApproachMartin Van Den Berghe, Nathan G Walworth, Neil C Dalvie, et al.
Microbial Cell Factories|May 12, 2026
Deletion of low-essentiality, secretion-associated genes enhances recombinant protein production in Komagataella phaffiiHayley Ford, Neil C Dalvie, Timothy R Lorgeree, et al.
Biotechnology and Bioengineering|November 15, 2024
Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffiiYuchen Yang, Neil C Dalvie, Joseph R Brady, et al.
Biotechnology and Bioengineering|February 24, 2021
Development of a platform process for the production and purification of single-domain antibodiesLaura E Crowell, Chaz Goodwine, Carla S Holt, et al.
Journal of Pharmaceutical Sciences|December 5, 2020
Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose VaccineKawaljit Kaur, Jian Xiong, Nishant Sawant, et al.
Biotechnology and Bioengineering|November 15, 2021
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffiiNeil C Dalvie, Andrew M Biedermann, Sergio A Rodriguez-Aponte, et al.
Biorxiv : the Preprint Server for Biology|April 21, 2021
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered <i>Komagataella phaffii</i>Neil C Dalvie, Andrew M Biedermann, Sergio A Rodriguez-Aponte, et al.
Human Vaccines & Immunotherapeutics|June 6, 2022
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvantsSakshi Bajoria, Kawaljit Kaur, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 7, 2020
Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine AntigensNishant Sawant, Kawaljit Kaur, David A Holland, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Microbial Cell Factories|July 31, 2024
CRISPR-Cas9 knockout screen informs efficient reduction of the Komagataella phaffii secretomeNeil C Dalvie, Timothy R Lorgeree, Yuchen Yang, et al.
Cold Spring Harbor Perspectives in Biology|October 3, 2023
Microbial Catalysis for CO<sub>2</sub> Sequestration: A Geobiological ApproachMartin Van Den Berghe, Nathan G Walworth, Neil C Dalvie, et al.
Microbial Cell Factories|May 12, 2026
Deletion of low-essentiality, secretion-associated genes enhances recombinant protein production in Komagataella phaffiiHayley Ford, Neil C Dalvie, Timothy R Lorgeree, et al.
Biotechnology and Bioengineering|November 15, 2024
Adaptation of Aglycosylated Monoclonal Antibodies for Improved Production in Komagataella phaffiiYuchen Yang, Neil C Dalvie, Joseph R Brady, et al.
Biotechnology and Bioengineering|February 24, 2021
Development of a platform process for the production and purification of single-domain antibodiesLaura E Crowell, Chaz Goodwine, Carla S Holt, et al.
Journal of Pharmaceutical Sciences|December 5, 2020
Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose VaccineKawaljit Kaur, Jian Xiong, Nishant Sawant, et al.
Biotechnology and Bioengineering|November 15, 2021
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor-binding domain in engineered Komagataella phaffiiNeil C Dalvie, Andrew M Biedermann, Sergio A Rodriguez-Aponte, et al.
Biorxiv : the Preprint Server for Biology|April 21, 2021
Scalable, methanol-free manufacturing of the SARS-CoV-2 receptor binding domain in engineered <i>Komagataella phaffii</i>Neil C Dalvie, Andrew M Biedermann, Sergio A Rodriguez-Aponte, et al.
Human Vaccines & Immunotherapeutics|June 6, 2022
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvantsSakshi Bajoria, Kawaljit Kaur, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 7, 2020
Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine AntigensNishant Sawant, Kawaljit Kaur, David A Holland, et al.
Pageof 3